|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epidemiology: Multiple Sclerosis - Improved diagnosis and survival are important drivers behind the current high levels of multiple sclerosis prevalence
Price: $5,700.00 (€4,492.42) ($6,840.00 (€5,390.90) Including VAT at 20%)
|
| Publication Date: 25-Mar-2011
Please click here for more information or to purchase this report at our partner store
Overview of multiple sclerosis definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year prevalent case forecast, and key patient segments across the seven major markets. |
|
|
Epidemiology: Epilepsy
Price: $5,700.00 (€4,492.42) ($6,840.00 (€5,390.90) Including VAT at 20%)
|
| Publication Date: 26-Mar-2011
Please click here for more information or to purchase this report at our partner store
Overview of epilepsy definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year prevalent case forecast, and key patient segments across the seven major markets. |
|
|
R&D Trends: Multiple Sclerosis - Progressive subtypes remain underserved in expansive pipeline
Price: $3,800.00 (€2,994.94) ($4,560.00 (€3,593.93) Including VAT at 20%)
|
| Publication Date: 26-Apr-2011
Please click here for more information or to purchase this report at our partner store
Review of key trends in the development of new MS drugs across the seven major markets. Also includes detailed analyses of clinical trial design, target product profile, innovative early-stage projects and future treatment developments. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Market Outlook for Neurodegenerative Diseases: Epidemiology, market size, current treatments and future innovation.
Price: $3,835.00 (€3,022.53) ($4,602.00 (€3,627.03) Including VAT at 20%)
|
| Publication Date: 20-Sep-2010
Please click here for more information or to purchase this report at our partner store
This report explores novel therapeutics that show promise to widen the therapeutic options for ND and also highlights the key commercialisation activities and developments of major players. This report hence offers essential market insight on the research and development trends for the ND area providing a rapid understanding of current therapeutics, their advantages and disadvantages, and the important pipeline candidates most likely to succeed in the marketplace. |
|
|
Alzheimer's Disease Market Forecast
Price: $15,200.00 (€11,979.77) ($18,240.00 (€14,375.73) Including VAT at 20%)
|
| Publication Date: 10-Nov-2010
Please click here for more information or to purchase this report at our partner store
Full analysis of the current and future Alzheimer's disease market. Includes sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) for key marketed brands, generics, and pipeline products. |
|
|
Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market
Price: $11,400.00 (€8,984.83) ($13,680.00 (€10,781.80) Including VAT at 20%)
|
| Publication Date: 12-May-2010
Please click here for more information or to purchase this report at our partner store
In-depth analysis of the epilepsy drug pipeline, including assessment of the clinical and commercial prospects of late-stage agents, unmet market needs, sales forecasts to 2019, and key opinion leader insight. |
|
|
Stakeholder Insight: Epilepsy - Neurologists remain loyal to brands in genericized market
Price: $15,200.00 (€11,979.77) ($18,240.00 (€14,375.73) Including VAT at 20%)
|
| Publication Date: 16-Dec-2010
Please click here for more information or to purchase this report at our partner store
Primary research-based analysis of the epilepsy market, based on a survey of 180 neurologists in the US, Japan, and EU. Includes epidemiology, patient segmentation, treatment trends, perception of key brands, and patient outcomes. |
|
|
Epidemiology: Alzheimer's Disease
Price: $5,700.00 (€4,492.42) ($6,840.00 (€5,390.90) Including VAT at 20%)
|
| Publication Date: 16-Dec-2010
Please click here for more information or to purchase this report at our partner store
Overview of Alzheimer's disease definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations and a 10 year prevalent case forecast for Alzheimer's disease across the seven major markets. |
|
|
Epidemiology: Parkinson's Disease
Price: $5,700.00 (€4,492.42) ($6,840.00 (€5,390.90) Including VAT at 20%)
|
| Publication Date: 10-Jan-2011
Please click here for more information or to purchase this report at our partner store
Overview of Parkinson's disease definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year prevalent case forecast, and key patient segments across the seven major markets. |
|
|
Parkinson's Disease Market Forecast
Price: $15,200.00 (€11,979.77) ($18,240.00 (€14,375.73) Including VAT at 20%)
|
| Publication Date: 16-Dec-2010
Please click here for more information or to purchase this report at our partner store
This datapack provides full analysis of the current and future Parkinson’s disease market, with forecasts to 2019 of current drugs and key pipeline products in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Multiple Sclerosis Market Forecast
Price: $15,200.00 (€11,979.77) ($18,240.00 (€14,375.73) Including VAT at 20%)
|
| Publication Date: 23-Dec-2009
Please click here for more information or to purchase this report at our partner store
Indication-specific sales value and volume forecasts for marketed multiple sclerosis brands and key pipeline products in the US, Japan, France, Germany, Italy, Spain, and the UK from 2008 to 2018. |
|
|
Stakeholder Opinions: Spinal Cord Injury - Attractive niche market with multi-billion dollar potential
Price: $3,800.00 (€2,994.94) ($4,560.00 (€3,593.93) Including VAT at 20%)
|
| Publication Date: 05-Mar-2010
Please click here for more information or to purchase this report at our partner store
Analysis of spinal cord injury epidemiology, unmet needs and pipeline treatments. Provides assessment of potential market value and analysis of opportunities and threats facing developers of SCI treatments based on interviews with key opinion leaders |
|
|
Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market
Price: $11,400.00 (€8,984.83) ($13,680.00 (€10,781.80) Including VAT at 20%)
|
| Publication Date: 12-May-2010
Please click here for more information or to purchase this report at our partner store
In-depth analysis of the epilepsy drug pipeline, including assessment of the clinical and commercial prospects of late-stage agents, unmet market needs, sales forecasts to 2019, and key opinion leader insight. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Be alerted by email of new featured reports
Browse upcoming events or submit your own